Literature DB >> 20816113

Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control.

Vincent J Carey1, Louise Bishop, Nancy Laranjo, Benjamin J Harshfield, Carolyn Kwiat, Frank M Sacks.   

Abstract

To determine the relative contributions of triglycerides (TGs) and high-density lipoprotein (HDL) cholesterol in the residual risk of coronary heart disease (CHD) after the reduction of low-density lipoprotein (LDL) cholesterol to guideline-recommended levels, we conducted a hospital-based, case-control study with optimal matching in the strata of LDL cholesterol, gender, ethnicity, and age. The 170 cases and 175 controls were patients at Brigham and Women's Hospital (Boston, Massachusetts) from 2005 to 2008 who had an LDL cholesterol level <130 mg/dl. The cases had incident CHD, and the controls had diagnoses unrelated to CHD. The 170 cases and 175 controls had a mean LDL cholesterol level of 73 and 87 mg/dl, respectively. The association between TG and HDL cholesterol levels and CHD risk was assessed using conditional and unconditional logistic regression analysis. The models investigated accommodated the possibility of an interaction between lipid factors. The odds of CHD increased by approximately 20% per 23-mg/dl increase in TGs and decreased by approximately 40% per 7.5-mg/dl decrease in HDL cholesterol. High TGs and low HDL cholesterol interacted synergistically to increase the odds ratio to 10 for the combined greatest TG (> or =190 mg/dl) and lowest HDL cholesterol quintiles (<30 mg/dl). High TG levels were more strongly associated with CHD when the HDL cholesterol was low than average or high; and low HDL cholesterol levels were more strongly associated with CHD when the TGs were high. TGs and HDL cholesterol were associated with CHD in patients with a LDL cholesterol level of < or =70 mg/dl, with a risk similar to, or greater than, those in the total group. In conclusion, high TG and low HDL cholesterol levels contribute strongly and synergistically to CHD when LDL cholesterol is well controlled. Thus, high TGs might have greater importance in patients with optimal rather than greater LDL cholesterol concentrations. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816113      PMCID: PMC4102341          DOI: 10.1016/j.amjcard.2010.05.002

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

Review 1.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

2.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Authors:  Philip Barter; Antonio M Gotto; John C LaRosa; Jaman Maroni; Michael Szarek; Scott M Grundy; John J P Kastelein; Vera Bittner; Jean-Charles Fruchart
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

3.  Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.

Authors:  Akio Kawakami; Masanori Aikawa; Pilar Alcaide; Francis W Luscinskas; Peter Libby; Frank M Sacks
Journal:  Circulation       Date:  2006-08-07       Impact factor: 29.690

Review 4.  Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis.

Authors:  Liam R Brunham; Roshni R Singaraja; Michael R Hayden
Journal:  Annu Rev Nutr       Date:  2006       Impact factor: 11.848

5.  Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.

Authors:  Chunyu Zheng; Christina Khoo; Katsunori Ikewaki; Frank M Sacks
Journal:  J Lipid Res       Date:  2007-02-21       Impact factor: 5.922

6.  VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.

Authors:  F M Sacks; P Alaupovic; L A Moye; T G Cole; B Sussex; M J Stampfer; M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

7.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

Authors:  Michael Miller; Christopher P Cannon; Sabina A Murphy; Jie Qin; Kausik K Ray; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2008-02-19       Impact factor: 24.094

8.  Lipid levels after acute coronary syndromes.

Authors:  Bertram Pitt; Joseph Loscalzo; Joseph Ycas; Joel S Raichlen
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

9.  Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.

Authors:  Nadeem Sarwar; John Danesh; Gudny Eiriksdottir; Gunnar Sigurdsson; Nick Wareham; Sheila Bingham; S Matthijs Boekholdt; Kay-Tee Khaw; Vilmundur Gudnason
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

10.  Extracting principal diagnosis, co-morbidity and smoking status for asthma research: evaluation of a natural language processing system.

Authors:  Qing T Zeng; Sergey Goryachev; Scott Weiss; Margarita Sordo; Shawn N Murphy; Ross Lazarus
Journal:  BMC Med Inform Decis Mak       Date:  2006-07-26       Impact factor: 2.796

View more
  40 in total

Review 1.  The epidemiological concept of residual risk.

Authors:  Diego Vanuzzo
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Correlation between biochemical indicators of blood lipid with cerebral vascular diseases.

Authors:  Dongmei Wang; Jun Hu; Qiao Ma; Jiarui Ma; Binjian Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  Coronary artery calcium: utilization for primary prevention of CHD.

Authors:  Harvey S Hecht
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 5.  The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

Authors:  Michael Clearfield; Melissa Pearce; Yasmin Nibbe; David Crotty; Alesia Wagner
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

6.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

7.  Triglyceride-to-HDL cholesterol ratio. Predictive value for CHD severity and new-onset heart failure.

Authors:  Z Yunke; L Guoping; C Zhenyue
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

Review 8.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

Review 9.  Dyslipidemias in the prevention of cardiovascular disease: risks and causality.

Authors:  Ian Graham; Marie-Therese Cooney; David Bradley; Alexandra Dudina; Zeljko Reiner
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

10.  A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.

Authors:  Fang Cui; Youliang Zhang; Qingmin Wei; Cuihua Liu; Junhui Wang; Meng Zhang
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.